Showing results (41-50 of 102) with videos related to

Sort By:
Pageof 11
BMC Urology|January 7, 2017
Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinomaJames A Kuzman, David D Stenehjem, Joseph Merriman, et al.
Ecancermedicalscience|October 13, 2016
Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2David M Gill, David D Stenehjem, Kinjal Parikh, et al.
Molecular Cancer Therapeutics|December 28, 2018
Germline Variant in <i>SLCO2B1</i> and Response to Abiraterone Acetate Plus Prednisone (AA) in New-onset Metastatic Castration-resistant Prostate Cancer (mCRPC)Andrew W Hahn, David M Gill, Austin Poole, et al.
Molecular Cancer Therapeutics|October 5, 2022
External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate CancerUmang Swami, Nicolas Sayegh, Yeonjung Jo, et al.
JAMA Network Open|March 28, 2024
Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020Alexander D Sherry, Andrew W Hahn, Zachary R McCaw, et al.
The Oncologist|April 1, 2021
Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor TherapiesAndrew J Wiele, Tharakeswara K Bathala, Andrew W Hahn, et al.
Cancer Treatment and Research Communications|July 24, 2020
Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancerMarcus Moses, Alex Niu, Michael B Lilly, et al.
The Canadian Journal of Urology|April 20, 2024
Optimizing outcomes in men with prostate cancer: the cardiovascular event lowering (CaELo) pathwaysDavid E Crawford, David Albala, Marc B Garnick, et al.
The Oncologist|August 23, 2021
Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy ResultsBenjamin L Maughan, Adam Kessel, Taylor Ryan McFarland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2020
Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate CancerNeeraj Agarwal, Roberto Nussenzveig, Andrew W Hahn, et al.
Pageof 11